


# Your patient has failed an AR-targeted therapy. What's next?

Determining the next treatment decision for your mCRPC patients who have failed an androgen receptor (AR)-targeted therapy can be challenging



## mCRPC diagnosis

### Patient information

- Age: 78
- Stage: metastatic castration-resistant prostate cancer (mCRPC)
- PSA level: 9.7 ng/mL
- ECOG performance status: 0
- Comorbidities: Diabetes, Osteoporosis

### Physician information

- Specialty: Nurse practitioner
- Physician practice: Advanced Urology Institute, Florida

## AR-targeted therapy failure



### Treatment(s) administered:

- Apalutamide for 12 months

### AR-targeted therapy failure indicated by:

- Rising PSA levels
- PET scan showed metastasis to lymph node



## Next treatment

### Reason(s) for Oncotype DX AR-V7 Nucleus Detect® testing

- Patient exhibited failure on apalutamide
- Physician was considering whether another AR-targeted therapy or taxane chemotherapy would be a more appropriate treatment. Although germline gene panel testing had already been completed, practitioner wanted to understand patient's AR-V7 status to determine best options at this stage.

Learn how the AR-V7 Nucleus Detect® assay helped guide this patient's next treatment


oncotypeDX®  
AR-V7 Nucleus Detect  
powered by Epic Sciences

ECOG = Eastern Cooperative Oncology Group; PSA = prostate-specific antigen.

## ONCOTYPE DX AR-V7 NUCLEUS DETECT® ASSAY

## Direct more mCRPC patients toward the right course of treatment

Oncotype DX AR-V7 Nucleus Detect assay can help guide your treatment decisions



Nuclear AR-V7

Negative



## Test results

- Result: AR-V7-
- **This means that AR-V7 protein was NOT detected in the nucleus of any circulating tumor cells (CTCs).** This patient may have clinical response to and benefit from a different AR-targeted therapy, regardless of prior lines of therapy<sup>1-3</sup>

## Post-test decision and outcomes

**Physician action:** Test results made it easy to discuss options with patient. Physician placed patient on abiraterone and prednisone.

**Patient reaction:** Relieved to find out that he had options other than chemotherapy.

**Patient response to treatment:** Patient has shown a sustained clinical response to abiraterone for over four months.

## ORDER NOW for your mCRPC patients

Contact your local Exact Sciences representative or Customer Service at 866 ONCOTYPE (866-662-6897).

Available  
and  
covered by  
Medicare

**References:** 1. Scher et al. *JAMA Oncol.* 2016. 2. Scher et al. *JAMA Oncol.* 2018. 3. Armstrong et al. *J Clin Oncol.* 2018.

Oncotype DX AR-V7 Nucleus Detect, AR-V7 Nucleus Detect, and Oncotype IQ are registered trademarks of Genomic Health, Inc., an Exact Sciences corporation. Exact Sciences is a registered trademark of Exact Sciences corporation. All other trademarks are the properties of their respective owners.

© 2020 Genomic Health, Inc., an Exact Sciences corporation. All rights reserved. GHI60075\_0120



oncotype DX®  
AR-V7 Nucleus Detect  
powered by Epic Sciences

EXACT  
SCIENCES